Rep. Mike Kelly Unloads Abbott Laboratories (NYSE:ABT) Shares

Key Points

• Rep. Mike Kelly sold Abbott Laboratories shares valued between $1,001 and $15,000 on July 17 from the Victoria Kelly Trust account; he also sold shares of PepsiCo and Walt Disney the same day.
• Abbott reported a quarterly earnings beat, with EPS of $1.31 versus the $1.28 consensus and revenue of $12.59 billion, up 13% year over year. The company reaffirmed 2026 guidance and declared a quarterly dividend of $0.63 per share, yielding about 2.3% annually.
• Wall Street maintains a Moderate Buy consensus on ABT, with an average price target of $118.17 versus the reported opening price of $110.92; the stock was trading up 1.1%.

Representative Mike Kelly (Republican-Pennsylvania) recently sold shares of Abbott Laboratories NYSE: ABT. In a filing disclosed on August 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on July 17th. The trade occurred in the Representative's "VICTORIA KELLY TRUST ICA" account.

Representative Mike Kelly also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of PepsiCo NASDAQ: PEP on 7/17/2026.
• Sold $1,001 - $15,000 in shares of Walt Disney NYSE: DIS on 7/17/2026.

Abbott Laboratories Trading Up 1.1%

NYSE:ABT opened at $110.92 on Thursday. The company has a market cap of $191.93 billion, a P/E ratio of 35.90, a price-to-earnings-growth ratio of 2.12 and a beta of 0.59. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49. The business has a 50 day moving average price of $96.86 and a two-hundred day moving average price of $99.73. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same period last year, the company earned $1.26 earnings per share. The firm's revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories's dividend payout ratio is 81.55%.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Citigroup boosted their price target on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a "buy" rating in a research report on Friday, July 17th. Sanford C. Bernstein lowered their target price on Abbott Laboratories from $125.00 to $110.00 and set an "outperform" rating on the stock in a research report on Friday, April 17th. Jefferies Financial Group dropped their target price on Abbott Laboratories from $145.00 to $135.00 and set a "buy" rating on the stock in a report on Friday, April 17th. Benchmark lowered their price target on Abbott Laboratories from $145.00 to $120.00 and set a "buy" rating on the stock in a research report on Friday, April 17th. Finally, Leerink Partners cut their price objective on Abbott Laboratories from $119.00 to $106.00 and set a "market perform" rating for the company in a report on Tuesday, April 21st. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $118.17.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Bank of America issues a Buy rating: The endorsement from Bank of America Securities adds to positive Wall Street sentiment and may support investor confidence in Abbott’s earnings and growth outlook. Abbott Laboratories Receives a Buy from Bank of America Securities
• Positive Sentiment: Abbott and Google expand glucose-monitoring partnership: Abbott will integrate Lingo glucose data with Google’s AI-driven consumer health tools. The companies also plan a large real-world metabolic-health study, potentially improving personalized coaching, supporting future Lingo features and increasing the commercial value of Abbott’s biowearable platform. Abbott Laboratories Ties Lingo Glucose Data to AI Health Tools
• Positive Sentiment: Potential cardiovascular innovation: Abbott’s ongoing PULSE study is evaluating early treatment for atrial fibrillation. Positive results could strengthen Abbott’s electrophysiology portfolio, although the study remains a longer-term catalyst and does not yet establish a commercial benefit. Early AF Treatment on Trial: What Abbott’s PULSE Study Could Mean for Investors
• Neutral Sentiment: Blood-donation campaign returns: Abbott and the Big Ten revived the “We Give Blood” campaign amid a U.S. blood shortage. The initiative enhances Abbott’s public profile and reinforces its healthcare mission, but it is unlikely to have a material near-term effect on earnings. Abbott and Big Ten Bring Back We Give Blood

Institutional Investors Weigh In On Abbott Laboratories

Several hedge funds have recently bought and sold shares of the company. MidAtlantic Capital Management Inc. bought a new position in shares of Abbott Laboratories during the 4th quarter worth approximately $25,000. Cornerstone Financial Management LLC acquired a new stake in Abbott Laboratories during the 4th quarter valued at $25,000. Purpose Unlimited Inc. bought a new position in Abbott Laboratories during the fourth quarter worth $25,000. Portfolio Resources Advisor Group Inc. acquired a new position in shares of Abbott Laboratories in the fourth quarter valued at $26,000. Finally, Abound Financial LLC bought a new position in shares of Abbott Laboratories in the fourth quarter valued at about $26,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

About Representative Kelly

Mike Kelly (Republican Party) is a member of the U.S. House, representing Pennsylvania's 16th Congressional District. He assumed office on January 3, 2019. His current term ends on January 3, 2027. Kelly (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 16th Congressional District. He declared candidacy for the 2026 election.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source